Sanofi Collaborates with Scribe Therapeutics in CRISPR Cell Therapy Deal
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)
Published: 3 Oct-2022
DOI: 10.3833/pdr.v2022.i10.2727 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In order to bolster its cell therapy pipeline, Sanofi has entered into a collaboration with Scribe Therapeutics to leverage the latter’s CRISPR technology to develop natural killer (NK) cell therapies for multiple oncology targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS